ChiCTR2600127198 版本V1.0 版本创建时间2026/06/26 14:15:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600127198 

最近更新日期:

Date of Last Refreshed on:

2026-06-26 14:15:32 

注册时间:

Date of Registration:

2026-06-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

颊黏膜移植术减少miok人工角膜移植术后并发症的前瞻性单臂临床研究

Public title:

A Prospective Single-Arm Clinical Study on Buccal Mucosa Grafting to Reduce Complications After miok Artificial Corneal Transplantation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

颊黏膜移植术减少miok人工角膜移植术后并发症的前瞻性单臂临床研究

Scientific title:

A Prospective Single-Arm Clinical Study on Buccal Mucosa Grafting to Reduce Complications After miok Artificial Corneal Transplantation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈俊曌 

研究负责人:

傅瑶 

Applicant:

Chen junzhao 

Study leader:

Yao Fu 

申请注册联系人电话:

Applicant telephone:

+86 21 23271699

研究负责人电话:

Study leader's
telephone:

+86 21 23271699

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lydie_007@126.com

研究负责人电子邮件:

Study leader's E-mail:

drfuyao@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市黄浦区制造局路639号

研究负责人通讯地址:

上海市黄浦区制造局路639号

Applicant address:

639 Manufacturing Bureau Road, Huangpu District, Shanghai

Study leader's address:

639 Manufacturing Bureau Road, Huangpu District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属第九人民医院

Applicant's institution:

The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

研究负责人所在单位:

上海交通大学医学院附属第九人民医院

Affiliation of the Leader:

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SH9H-2026-T245-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院附属第九人民医院研究者发起的临床研究伦理审查专委会

Name of the ethic committee:

Ethics Review Committee for clinical research initiated by researchers

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-23 00:00:00

伦理委员会联系人:

甄红

Contact Name of the ethic committee:

Zhen Hong

伦理委员会联系地址:

上海市黄浦区制造局路639号

Contact Address of the ethic committee:

639 Manufacturing Bureau Road, Huangpu District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 23271699

伦理委员会联系人邮箱:

Contact email of the ethic committee:

shjyiec@126.com

研究实施负责(组长)单位:

上海交通大学医学院附属第九人民医院

Primary sponsor:

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

研究实施负责(组长)单位地址:

上海市黄浦区制造局路639号

Primary sponsor's address:

639 Manufacturing Bureau Road, Huangpu District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属第九人民医院

具体地址:

上海市黄浦区制造局路639号

Institution
hospital:

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

Address:

639 Manufacturing Bureau Road, Huangpu District, Shanghai

经费或物资来源:

研究型病房专项基金

Source(s) of funding:

Research Ward Special Fund

研究疾病:

各种原因造成的角膜损伤导致的双眼角膜盲患者  

Target disease:

Patients with bilateral corneal blindness caused by various types of corneal damage

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

对受试者进行Miok人工角膜移植术联合颊黏膜移植术,随访观察联合手术疗效及术后1年内人工角膜前膜发生情况,并与已发表的术后并发症发生率进行比较,评估颊黏膜移植术对手术疗效以及减少人工角膜前膜的作用。 评估颊黏膜移植术在减少术后角膜变薄溶解、人工角膜支架暴露等并发症中的作用。  

Objectives of Study:

137/1000The subjects underwent Miok artificial corneal transplantation combined with buccal mucosal transplantation. The efficacy of the combined surgery and the occurrence of artificial corneal anterior membrane formation within one year postoperatively were followed up and compared with the published incidence of postoperative complications to evaluate the role of buccal mucosal transplantation in surgical efficacy and in reducing artificial corneal anterior membrane formation. The role of buccal mucosal transplantation in mitigating postoperative complications such as corneal thinning, dissolution, and exposure of the artificial corneal scaffold was also assessed.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18岁。
2.双眼角膜盲患者,视力为眼前指数或更差,但至少为光感,光定位好,色觉正常。
3.同种异体角膜移植无成功希望,或即使角膜移植手术能够进行但无法保持角膜透明性的患者。
4.电生理显示功能尚好,B超显示视网膜结构正常者,无明显视盘凹陷,有提高视功能的潜能。
5.眼压正常或经过青光眼治疗眼压控制稳定的患者。
6.原发病稳定,无活动性炎症和感染者。
7.受试者自愿参加本试验并且签署知情同意书,能配合治疗且按照要求定期随访者。

Inclusion criteria

1.Age >= 18 years old; 2.Patients with binocular corneal blindness have visual acuity of anterior visual index or worse, but at least light perception, good light localization, and normal color vision; 3.Patients who have no hope of success in allogeneic corneal transplantation, or who cannot maintain corneal transparency even if corneal transplantation surgery can be performed; 4.The electrophysiological display function is still good, and B-ultrasound shows normal retinal structure without obvious optic disc depression, which has the potential to improve visual function; 5.Patients with normal intraocular pressure or stable intraocular pressure control after glaucoma treatment; 6.The primary disease is stable, with no active inflammation or infected individuals; 7.The subjects voluntarily participate in this trial and sign an informed consent form. They are able to cooperate with the treatment and follow up regularly as required.

排除标准:

1.经同种异体角膜移植手术能获得较好疗效者。
2.光定位、红色觉、电生理功能较差者。
3.B超显示眼底结构异常者。
4.患有青光眼,眼压无法控制的患者。
5.眼部有活动性炎症或感染者。
6.患者严重全身疾病,病情不稳定或无法控制的患者。
7.有严重的精神疾病史。
8.妊娠或准备妊娠的妇女。
9.严重的酒精依赖或药物滥用者。
10.研究者认为不适宜参加本项目临床研究者。

Exclusion criteria:

1.Patients who can achieve good therapeutic effects through allogeneic corneal transplantation surgery; 2.Individuals with poor optical localization, red perception, and electrophysiological functions; 3.Ultrasound shows abnormal fundus structure; 4.Patients with glaucoma and uncontrolled intraocular pressure; 5.Individuals with active inflammation or infection in the eyes; 6.Patients with severe systemic diseases, unstable or uncontrollable conditions; 7.Has a history of serious mental illness; 8.Women who are pregnant or preparing to become pregnant; 9.Serious alcohol dependence or drug abuse; 10.The researchers believe that it is not suitable for clinical researchers to participate in this project.

研究实施时间:

Study execute time:

From 2026-06-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-26 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

10

Group:

Treat group

Sample size:

干预措施:

颊黏膜移植

干预措施代码:

Intervention:

Buccal mucosal transplantation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属第九人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后严重并发症

指标类型:

次要指标

Outcome:

Postoperative best corrected visual acuity

Type:

Secondary indicator

测量时间点:

术后1年

测量方法:

视力丧失,眼部B超提示发生眼内炎、视网膜脱离等情况

Measure time point of outcome:

1 year after surgery

Measure method:

Vision loss, eye ultrasound indicates the occurrence of endophthalmitis, retinal detachment, and other conditions.

指标中文名:

术后角膜变薄溶解,人工角膜支架暴露

指标类型:

次要指标

Outcome:

Postoperative best corrected visual acuity

Type:

Secondary indicator

测量时间点:

术后1年

测量方法:

最佳矫正视力不变情况下,屈光度增加≥-2D; 眼前段照相显示镜柱逆时针旋转大于90°;前节OCT显示镜柱高度前凸大于1mm。

Measure time point of outcome:

1 year after surgery

Measure method:

Under the condition of unchanged best corrected visual acuity, the refractive error increases by ≥ -2D; the front segment of the eye shows a counterclockwise rotation of the lens column greater than 90 °; The OCT in the previous section showed that the height of the mirror column had a protrusion greater than 1mm.

指标中文名:

术后最佳矫正视力

指标类型:

主要指标

Outcome:

Postoperative best corrected visual acuity

Type:

Primary indicator

测量时间点:

术后

测量方法:

Snellen视力表

Measure time point of outcome:

1 year after surgery

Measure method:

Snellen visual acuity chart

指标中文名:

术后人工角膜前膜发生情况

指标类型:

主要指标

Outcome:

Postoperative best corrected visual acuity

Type:

Primary indicator

测量时间点:

术后1年

测量方法:

裂隙灯检查,眼前节照相

Measure time point of outcome:

1 year after surgery

Measure method:

Crack lamp inspection, anterior segment photography

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

文章发表后6个月内,经研究者同意后可邮箱申请获取方式;

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the article is published, you can email to request access with the researcher's consent.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-26 14:15:32